Literature DB >> 8139766

Effects of chelators on iron uptake and release by the brain in the rat.

A Crowe1, E H Morgan.   

Abstract

The iron chelators desferrioxamine (DFO), pyridoxal isonicotinoyl hydrazone (PIH), 2,2'-bipyridine, diethylenetriamine penta-acetic acid (DTPA) and 1,2 dimethyl-3-hydroxy pyrid-4-one (CP20) were analysed for their ability to change 59Fe uptake and release from the brain of 15- and 63-day rats either during or after intravenous injection of 59Fe-125I-transferrin. DTPA was the only chelator unable to significantly reduce iron uptake into the brain of 15-day rats. This indicates that iron is not released from transferrin at the luminal surface of brain capillary endothelial cells. CP20 was able to reduce iron uptake in the brain by 85% compared to 28% with DFO. Only CP20 was able to significantly reduce brain iron uptake in 63 day rats. Once 59Fe had entered the brain no chelator used was able to mediate its release. All of the chelators except CP20 had similar effects on femur iron uptake as they did on brain uptake, suggesting similar iron uptake mechanisms. It is concluded that during the passage of transferrin-bound iron into the brain the iron is released from transferrin within endothelial cells after endocytosis of transferrin.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8139766     DOI: 10.1007/bf00966731

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  20 in total

1.  THE BIOCHEMISTRY OF DESFERRIOXAMINE AND ITS RELATION TO IRON METABOLISM.

Authors:  H KEBERLE
Journal:  Ann N Y Acad Sci       Date:  1964-10-07       Impact factor: 5.691

Review 2.  Receptor-mediated peptide transport through the blood-brain barrier.

Authors:  W M Pardridge
Journal:  Endocr Rev       Date:  1986-08       Impact factor: 19.871

3.  The effects of an antibody to the rat transferrin receptor and of rat serum albumin on the uptake of diferric transferrin by rat hepatocytes.

Authors:  D Trinder; E H Morgan; E Baker
Journal:  Biochim Biophys Acta       Date:  1988-09-01

4.  Transferrin and iron uptake by the liver in the rat.

Authors:  M E Gardiner; E H Morgan
Journal:  Aust J Exp Biol Med Sci       Date:  1974-10

5.  The study of iron mobilisation from transferrin using alpha-ketohydroxy heteroaromatic chelators.

Authors:  G J Kontoghiorghes
Journal:  Biochim Biophys Acta       Date:  1986-01-30

6.  Developmental changes in transferrin and iron uptake by the brain in the rat.

Authors:  E M Taylor; E H Morgan
Journal:  Brain Res Dev Brain Res       Date:  1990-08-01

7.  Anemia of the Belgrade rat: evidence for defective membrane transport of iron.

Authors:  B J Bowen; E H Morgan
Journal:  Blood       Date:  1987-07       Impact factor: 22.113

8.  Human blood-brain barrier transferrin receptor.

Authors:  W M Pardridge; J Eisenberg; J Yang
Journal:  Metabolism       Date:  1987-09       Impact factor: 8.694

9.  Cellular pharmacology of deferrioxamine B and derivatives in cultured rat hepatocytes in relation to iron mobilization.

Authors:  R Laub; Y J Schneider; J N Octave; A Trouet; R R Crichton
Journal:  Biochem Pharmacol       Date:  1985-04-15       Impact factor: 5.858

10.  Iron uptake in relation to transferrin degradation in brain and other tissues of rats.

Authors:  M E Strahan; A Crowe; E H Morgan
Journal:  Am J Physiol       Date:  1992-10
View more
  11 in total

1.  Nanoparticle-chelator conjugates as inhibitors of amyloid-beta aggregation and neurotoxicity: a novel therapeutic approach for Alzheimer disease.

Authors:  Gang Liu; Ping Men; Wataru Kudo; George Perry; Mark A Smith
Journal:  Neurosci Lett       Date:  2009-03-25       Impact factor: 3.046

2.  Nanoparticle and iron chelators as a potential novel Alzheimer therapy.

Authors:  Gang Liu; Ping Men; George Perry; Mark A Smith
Journal:  Methods Mol Biol       Date:  2010

3.  The synthesized transporter K16APoE enabled the therapeutic HAYED peptide to cross the blood-brain barrier and remove excess iron and radicals in the brain, thus easing Alzheimer's disease.

Authors:  Zhenyou Zou; Qiqiong Shen; Yanxia Pang; Xin Li; Yongfeng Chen; Xinjuan Wang; Xinhua Luo; Zhongmin Wu; Zhaosheng Bao; Juanli Zhang; Jiawei Liang; Lingjia Kong; Lunan Yan; Lijun Xiong; Tianjun Zhu; Shuaibin Yuan; Miaoyang Wang; Kewei Cai; Yinning Yao; Jianchao Wu; Yuding Jiang; Heng Liu; Jing Liu; Yan Zhou; Qianqian Dong; Wei Wang; Kangjie Zhu; Li Li; Yingjie Lou; Hongdian Wang; Yizi Li; Hong Lin
Journal:  Drug Deliv Transl Res       Date:  2019-02       Impact factor: 4.617

Review 4.  Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice.

Authors:  J Lan; D H Jiang
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

Review 5.  Nanoparticle delivery of transition-metal chelators to the brain: Oxidative stress will never see it coming!

Authors:  David J Bonda; Gang Liu; Ping Men; George Perry; Mark A Smith; Xiongwei Zhu
Journal:  CNS Neurol Disord Drug Targets       Date:  2012-02       Impact factor: 4.388

Review 6.  Transferrin and transferrin receptor function in brain barrier systems.

Authors:  T Moos; E H Morgan
Journal:  Cell Mol Neurobiol       Date:  2000-02       Impact factor: 5.046

7.  Metal chelators coupled with nanoparticles as potential therapeutic agents for Alzheimer's disease.

Authors:  Gang Liu; Ping Men; George Perry; Mark A Smith
Journal:  J Nanoneurosci       Date:  2009-06-01

Review 8.  Neurodegenerative disorders and nanoformulated drug development.

Authors:  Ari Nowacek; Lisa M Kosloski; Howard E Gendelman
Journal:  Nanomedicine (Lond)       Date:  2009-07       Impact factor: 5.307

Review 9.  Iron chelation and multiple sclerosis.

Authors:  Kelsey J Weigel; Sharon G Lynch; Steven M LeVine
Journal:  ASN Neuro       Date:  2014-01-30       Impact factor: 4.146

10.  Linking the low-density lipoprotein receptor-binding segment enables the therapeutic 5-YHEDA peptide to cross the blood-brain barrier and scavenge excess iron and radicals in the brain of senescent mice.

Authors:  Zhenyou Zou; Shengxi Shao; Ruyi Zou; Jini Qi; Liguan Chen; Hui Zhang; Qiqiong Shen; Yue Yang; Liman Ma; Ruzeng Guo; Hongwen Li; Haibo Tian; Pengxin Li; Mingfang Yu; Lu Wang; Wenjuan Kong; Caiyu Li; Zhenhai Yu; Yuping Huang; Li Chen; Qi Shao; Xinyan Gao; Xiaolin Chen; Zhengbo Zhang; Jianguo Yan; Xiaoyun Shao; Ru Pan; Lu Xu; Jing Fang; Lei Zhao; Yaohui Huang; Anqi Li; Yuchong Zhang; Wenkao Huang; Kechun Tian; Minxin Hu; Linchao Xie; Lingbin Wu; Yu Wu; Zhen Luo; Wenxin Xiao; Shanshan Ma; Jianan Wang; Kaixin Huang; Siyuan He; Fan Yang; Shuni Zhou; Mo Jia; Hui Zhang; Hongsheng Lu; Xinjuan Wang; Jie Tan
Journal:  Alzheimers Dement (N Y)       Date:  2019-11-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.